Premier Graphene Inc BIEI

2000% in a few weeks, 10000% and more in a year ...

[badgirl007]

from Friday 22. 02. 2019 - USD 0.0355 - and after the upcoming news. 

"Here we go!! 

In Case You Missed It -- Uptick Newswire Hosts Premier Biomedical, Inc. on The Stock Day Podcast to Discuss The Company's Current Projects 
Jackson Center, PA, February 19, 2019 -- Premier Biomedical, Inc. (OTC: BIEI) President & CEO, William A. Hartman discussed progress the company has made on a number of fronts since his last appearance on Uptick Newswire's "Stock Day" podcast. 

Jolly began the interview by asking Hartman to give an update to listeners about the Company's current projects. Hartman explained the Company was previously strictly a R&D based business. This went well for the Company, they were forced to put their very successful projects, including a cure for PTSD as well as an anti-breast cancer drug on the shelf and morph the company into developing and marketing a revenue-producing series of hemp oil/CBD topical pain-relieving products. 

To explain the Company's current position, Hartman shared a letter with listeners that the company sent out recently to 29 of its Directors, Officers, and sales force. Hartman also stated that the letter would soon be sent out to the company's stockholders and its e-mail distribution list. 

The letter stated: "We currently have eight topical, all-natural, 50-state- legal, pesticide- and solvent-free, hemp oil/CBD, topical pain relief products that, we believe, are the very best on the market." 

Hartman shared that the products developed by the Company are created with a proprietary formula, which makes them more effective than competitors and at a lower price. "Unsolicited testimonies from satisfied customers validate our claims.", added Hartman. 

Hartman also explained that the Company has sold most of their products online to date, with some smaller percentage of sales to pharmacies and medical facilities. However, the Company received a serious blow to its online sales when Amazon refused to list any products on their platform with CBD listed as an ingredient. Hartman is optimistic that the passing of the 2018 Farm Bill will eventually shift Amazon's stance on the subject, but it may take some time. 

In the interim, the Company will be reestablishing their position on Amazon by creating a product line labeled, "Nature's Own Pain Relief". This product line will not have CBD listed on the label and will therefore comply with Amazon's guidelines. The Company will also be expanding their sales via direct distribution to retail establishments. 

Premier Biomedical has recently been working with a large distributor that has access to convenience store marketing and sales. The distributor challenged the Company to produce a line of products that would retail for under ten dollars. Hartman explained that Premier worked very hard to develop a total of four new "Intro" products that would retail at or below this price point. 

"We're very excited about these new products, but unfortunately, manufacturing availability is waiting on the purchase order for some or all of these products from the distributor, explained Hartman. He also added that he expects the purchase order to occur within the first quarter. 

Hartman then shared that the distributor's plan is to try these products out in up to 1,000 stores, and, if successful, expand into 10,000 stores nationwide. Meanwhile, the Company is working on preparing to market its entire line of Premium Products under the new name: "Nature's Own Pain Relief" label. 

The Company has also partnered with an additional distributor and will be altering their price points to perform more competitively in the market. Once these changes occur, the Company expects sales to increase exponentially. 

Hartman explained that another distributorship for the Company revolves around military and long-term care sales, which represent massive potential revenues. Hartman emphasized that a major impetus in the growth of the hemp oil/CBD business is the fact that Premier's products are an alternative to dangerous and addictive opioid pain medications that are a major contributor to the almost 200 drug overdose deaths per day in the country. 

Hartman closed by sharing that the Company plans to proceed aggressively with their two-pronged sales strategy and expansion to become an even larger force in the industry. Hartman also shared his interest in potential partnerships, both domestic and foreign, and what they could mean for the potential of the Company. "

https://www.premierbiomedical.com/in-case-you-missed-it-uptick-newswire-hosts-premier-biomedical-inc-on-the-stock-day-podcast/

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147060627